23 Feb Sernova
Cynthia Pussinen, CEO
April 9 | 10:30am | Salone dei Cavalieri, Section 2
London Ontario, Canada
(TSX: SVA; OTCQB: SEOVF; FSE/XETRA: PSH)
Sernova is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and hemophilia A. The Company is focused on developing a ‘functional cure for insulin-dependent diabetes with its lead asset, the Cell Pouch System, a novel implantable and scalable cell therapy platform transplanted initially with human donor islets but ultimately using an iPSC islet like cluster technology exclusively licensed from Evotec SE. Sernova is progressing a Phase 1/2 clinical trial evaluating the Cell Pouch System in patients with T1D with impaired hypoglycemia awareness. Of six patients in the first cohort of the trial, five are now insulin-independent, with the first patient at almost four years without the need for insulin injections and a normalized HbA1c. Enrollment in a second cohort of patients, which employs a higher capacity Cell Pouch System, to be completed shortly with data to come in 2024.
